S H Kelkar Targets Double-Digit Growth Despite Margin Uncertainty

S H Kelkar and Company Limited — Q1 FY27 Earnings Call (held July 29, 2026)

1. Overall Tone of Management: Optimistic

• Management highlights “sustained solid performance”, “encouraging revenue growth” and “improvement in operating profitability.”
• They repeatedly emphasize confidence in full-year delivery: “keeps us on track to deliver double-digit revenue growth and improved margins for the full year.”
• However, they temper this with caution on macro/geopolitics (“operating environment continues to warrant caution”, “cautious on the overall environment”), but the dominant tone remains constructive.

2. Key Themes from Management Commentary

• Growth + mix benefits
• Consolidated revenue up 14% YoY to Rs. 662 crore.
• Fragrance growth led by Europe and select international markets; management notes performance despite “subdued consumer backdrop” in developed markets.
• Flavours delivered “strong broad-based growth,” with explicit acknowledgment that some growth is order-timing/lumpiness.
• Margin resilience despite volatility
• Gross margins stable YoY, supported by “favourable product mix and proactive raw material planning.”
• EBITDA up 21%; EBITDA margin improved to 13.4% vs 12.6% prior year, attributed to operating leverage.
• Deliberate investment ahead of demand
• Continued strengthening of R&D and Creative Development Centers (CDCs) and manufacturing capabilities.
• Management admits near-term cost pressure: “These investments carry near-term costs… they will weigh on segment margins until the corresponding revenue scale up.”
• Supply continuity as a strategic priority
• “Strategic inventory buildup” to ensure supply security amid “fluid global supply environment.”
• They claim proactive planning prevented interruptions: “without any interruption despite the fluid global supply environment.”
• Balance sheet trade-off: higher net debt
• Net debt increased by Rs. 65 crore to Rs. 852 crore (June 2026), driven by inventory buildup + capacity/growth capex.
• Still committed to deleveraging: “firmly committed to deleveraging in the medium to long term.”
• Insurance claim tailwind
• “Exceptional income of approximately Rs. 30 crore” from fire-related insurance; expects full settlement within FY27.

3. Q&A Analysis

Theme A: Flavours outlook, lumpy orders, and normalization

• Core questions
• Full-year outlook for Flavours growth and whether Q1 strength is repeatable.
• Clarify India Fragrance softness (flat YoY) and whether it’s base-effect/timing.
• Quantify FX contribution to revenue growth.
• Management response
• Flavours: management provides a “normal basis” estimate:
  • Q1 Flavours revenue Rs. 112 crore
  • “ballpark Rs. 95 crore would be on a normal basis”
  • expects preponement effects and extra stock buildup; July momentum intact.
• India Fragrance softness:
  • Q1 last year was strong; management also references portfolio discipline:
  • “conscious decision… to exit from some low-margin businesses”
  • “held back on our sales to clients” and only supplied what clients “regularly consume” due to raw material confidence.
  • claims servicing “almost all the clients now” after inventory buildup.
• FX:
  • “9% is the like-for-like growth and net-net 5% is our additional FX sales”
• Notable/partial aspects
• They do not give a full-year Flavours growth %, only quarterly normalization run-rate estimates.
• The normalization relies on assumptions about preponement and distribution stocking, which can be hard to verify.

Theme B: Margins—sustainability and full-year range

• Core questions
• Whether EBITDA margin expansion is realistic; provide a full-year margin range.
• Whether gross margins will remain at current levels amid volatility.
• Sustainability of Flavours margins.
• Management response
• They avoid a precise full-year % range:
  • “if there are no big changes, we should look at similar sort of margin and growth”
  • “baseline normal quarter” (Q1 not “exceptional”)
• They emphasize uncertainty: geopolitical + demand mix could move results; percentages may vary “1% here and there.”
• Notable/partial aspects
• Analyst asked for a range (e.g., 10–12% EBITDA). Management did not commit to a numeric band.
• They imply margin stability but also repeatedly stress macro uncertainty.

Theme C: Capex, factory rebuild timeline, and debt trajectory

• Core questions
• Update on factory rebuild/commissioning (Vanavate, Vashivali) and capex phasing.
• Whether debt will increase further; tax rate guidance.
• Capex done in Q1 and split Europe vs India.
• Management response
• Commissioning: Vanvate in Q3.
• Debt: expected “broadly at the June level,” may “slightly go up in September.”
• Capex phasing:
  • Rs. 25 crore Europe in Q1; European capex “completed,” plant operational since May.
  • Q2 capex continues on Vanvate and Vashivali; bulk before end of Q2.
  • Remaining capex decision between Q4 vs Q1 next year for Vashivali upgradation.
• Tax rate:
  • ETR around 31.5%–32% in Q1; target <30%.
• Notable/partial aspects
• They provide capex timing but not a full FY27 capex number in this call (earlier calls had numbers; here it’s more phasing-focused).

Theme D: European expansion economics (ROCE/ROIC) and ramp-up

• Core questions
• European CDC ramp-up timing, expected revenue stream, and return ratios.
• Group-level ROE/ROCE targets.
• Management response
• Europe ROCE target: 17%–18%.
• Ramp-up: “It will take 3 to 4 years of growth to come back to the normal trend line.”
• Additional R&D investment: “roughly $3 million a year.”
• Group ROCE:
  • “excess of 15% ROCE” target; long-term 20% ROCE.
  • “3 to 5 years of slow traction” toward 15%.
• Notable/strong answers
• They give explicit return targets and a time horizon, which is clearer than margin guidance.

Theme E: Raw material volatility—inventory strategy and margin protection

• Core questions
• Whether strategic inventory is benefiting gross margin now and whether it could hurt later.
• Whether EBITDA should expand as fixed CDC investments are “largely done.”
• Management response
• Inventory visibility: “6 months visibility” and “extra 45 days of inventory.”
• They claim no big cost pressure for next ~6 months due to fixed pricing/contracting.
• On EBITDA expansion: they refuse to forecast full-year because demand structure is uncertain:
  • “not in a sort of position to anticipate or predict the demand situation for the full year”
• Notable/partial aspects
• They provide a strong inventory-based margin defense, but then walk back EBITDA expansion predictability.

Theme F: Global Ingredients softness and insurance claim

• Core questions
• Turnaround expectations for Global Ingredients.
• Remaining insurance claim amount and settlement timing.
• Management response
• Global Ingredients: “softer quarter” due to supply gap; expects recovery in second half.
• Insurance:
  • Pending claim: “Rs. 60 crore is the claim amount pending”
  • Continue chasing insurers to fulfill within FY27.
• Notable/strong answers
• They quantify pending claim and settlement expectation.

Theme G: US/UK/Europe traction and revenue expectations

• Core questions
• Ramp-up in European subsidiary and traction in US/UK.
• Whether Unilever/global accounts are adding new RFIs/RFPs.
• Management response
• US: expects ~$1.5m to $2m minimum revenue for the year.
• UK: “early days,” need 12 to 15 months before substantial business materializes.
• Unilever/global accounts: no “large breakthrough significant additions”; pipeline continues but ramp is slower.
• Notable/partial aspects
• They give US revenue expectation but no quantified UK or Europe revenue.

4. Guidance / Outlook

Explicit guidance (quantitative)

• Full-year growth/margins (qualitative but with targets implied)
• “double-digit revenue growth and improved margins for the full year” (no numeric % given).
• Flavours normalization run-rate
• Q1 Flavours: Rs. 112 crore
• “normal basis” estimate: Rs. 95–96 crore per quarter
• Q2 expected “better than Rs. 95–96 crore” (no exact number).
• Capex phasing
• Europe capex: Rs. 25 crore in Q1, completed; plant operational since May.
• Q2 Vanvate capex: ~Rs. 25 crore
• Remaining India capex: “around Rs. 50 crore” (decision Q4 vs Q1 next year).
• Debt
• Debt expected “broadly at the June level,” possible slight increase in September.
• Tax
• ETR target: <30% (working on it); current 31.5%–32%.
• European returns
• Europe ROCE: 17%–18%
• Group ROCE: target excess of 15%, long-term 20%
• US revenue
• US: $1.5m to $2m minimum revenue for FY27 (as stated in Q&A).

Implicit signals (qualitative)

• Macro caution without demand collapse
• They “are cautious on the overall environment” and won’t predict macro growth, but claim “fundamental demand drivers… have remained intact and continued to grow.”
• Margin stability bias
• Management repeatedly frames Q1 as “baseline normal quarter” and expects similar margin levels unless disruptions occur.
• Portfolio discipline continues
• India softness attributed to exiting low-margin businesses and limiting advanced orders due to raw material uncertainty—suggesting continued margin-protection even if it can suppress reported growth.

5. Standout Statements (direct quotes where useful)

• On macro uncertainty
• “operating environment continues to warrant caution”
• “We are not looking to predict the environment… but to be prepared for rapid changes.”
• On investment philosophy
• “We have invested ahead of demand in the R&D and Creative Development Centers and manufacturing capabilities.”
• “These investments carry near-term costs… but they are what position us to win larger briefs”
• On supply continuity
• “support customers without any interruption despite the fluid global supply environment.”
• On Flavours lumpy growth
• “a portion of this growth reflects the timing of certain customer orders”
• “ballpark Rs. 95 crore would be on a normal basis”
• On margin predictability
• “we should look at similar sort of margin and growth” (if no big changes)
• Yet later: “not in a sort of position to anticipate or predict the demand situation for the full year”
• On debt
• “net debt increased… This reflects 2 conscious decisions: strategic inventory buildup… and continued capital deployment”
• “firmly committed to deleveraging”
• On European ramp
• “It will take 3 to 4 years of growth to come back to the normal trend line.”
• On US/UK
• US: “expect to do about 1.5 million to 2 million minimum revenue for the year”
• UK: “wait at least 12 to 15 months before substantial businesses are materializing.”

6. Red Flags / Positive Signals

Red flags
– Guidance restraint / non-commitment on margins
– They avoid giving a numeric full-year EBITDA margin range despite analyst requests.
– Dependence on timing effects
– Flavours growth normalization depends on preponement and inventory stocking; risk that normalization is slower than expected.
– Demand uncertainty used to limit forecasting
– They cite inability to predict full-year demand structure, which can also mask downside risk.
– Debt rising while investing
– Net debt up Rs. 65 crore; deleveraging is promised but near-term leverage remains a concern.

Positive signals
– Clear operational controls
– Inventory strategy with “6 months visibility” and contracts/pricing discipline.
– Quantified capex and commissioning milestones
– Vanvate commissioning in Q3; Europe capex completed and plant operational.
– Insurance claim quantified
– Pending claim and expectation of settlement within FY27 reduces uncertainty on one-off income.
– Return targets for Europe
– ROCE targets (17–18%) and group ROCE roadmap (15% then 20%) provide a framework.

7. Historical Comparison & Consistency Analysis (vs prior 3 calls provided)

a. Change in Tone Over Time

• Current (Q1 FY27): More Optimistic / Confident
• Stronger emphasis on “baseline normal quarter” and “on track” for full-year double-digit growth + improved margins.
• Prior calls
• Q4 & FY26 (May 18, 2026): cautious but framed as “broadly in line with stated guidance,” with margin protection focus and portfolio optimization.
• Q3 & 9M FY26 (Feb 9, 2026): investment phase acknowledged; margins pressured by execution costs; debt near-term increase discussed.
• Q2 & H1 FY26 (Nov 12, 2025): more explicit about margin improvement path (gross margin improving, EBITDA muted due to initiatives).
• Shift drivers
• Q1 FY27 shows better reported profitability (EBITDA margin up YoY) and more concrete commissioning/capex phasing (Vanvate Q3).
• Still cautious on macro, but less defensive than earlier calls.

b. Tracking Past Commitments vs Outcomes

1) “Gross margin improvement” directionality
– Past statement (Q2 & H1 FY26, Nov 2025):
– “Things will improve from here further 1%, 1%, 1.5%”
– What happened / current evidence (Q1 FY27):
– Gross margins “stable year-on-year” (not a clear step-up).
– Flag: ⏳ Delayed / Not clearly delivered (improvement not demonstrated as a sustained step-up; stability is reported).

2) Margin expansion to teens / low-teens
– Past statement (Q4 & FY26, May 2026):
– Management discussed maintaining margins and aiming for normalization; also referenced adjusted EBITDA around mid-13% in “normal environment.”
– Current (Q1 FY27):
– EBITDA margin 13.4% (improved YoY).
– Flag: ✅ Partially delivered (improvement vs prior year, but still not “expanded” dramatically).

3) Capex cycle and return ramp
– Past statement (Q3 & 9M FY26, Feb 2026):
– Investments would take time; “2 years” to generate positive cash flow revenues in Europe/America (as later reiterated).
– Current (Q1 FY27):
– Europe ROCE ramp: “3 to 4 years” to return to normal trend line; group ROCE 15% over 3–5 years.
– Flag: ✅ Consistent (time horizons remain aligned; no sudden acceleration promised).

4) Insurance claim settlement
– Past statement (Q3 & 9M FY26, Feb 2026):
– Expect insurance money within 6–12 months.
– Current (Q1 FY27):
– Exceptional income Rs. 30 crore recognized; expects full settlement within FY27.
– Flag: ✅ On track (at least partial settlement realized; full settlement still pending but timeline maintained).

c. Narrative Shifts

• From “margin protection under inflation” → “baseline normal quarter + investment discipline”
• Earlier calls leaned heavily on inflation/raw material shocks and uncertainty.
• Q1 FY27 leans more on investment as a deliberate growth enabler while claiming Q1 is not exceptional.
• Flavours now framed as a key near-term driver
• Q1 FY27 provides more granular normalization math for Flavours than earlier calls did.
• Global Ingredients remains a recurring drag
• Q1 FY27: “softer quarter… watching closely.”
• Earlier calls also referenced muted/negative headwinds in ingredients.

d. Consistency & Credibility Signals

• Medium credibility
• Positives: quantified capex phasing, inventory visibility, insurance claim progress, and return targets.
• Concerns: repeated use of “timing effects” (Flavours) and “cannot predict full-year demand” limits verifiability of margin/growth claims.
• No clear pattern of outright contradictions, but forecast precision remains low.

e. Evolution of Key Themes

• Demand/macro
• Direction: Stable to cautious (demand drivers